{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:51:35Z","timestamp":1791384695535,"version":"4.3.3"},"reference-count":129,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.parkreldis.2014.12.013","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T08:10:49Z","timestamp":1419063049000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Update on Huntington's disease: Advances in care and emerging therapeutic options"],"prefix":"10.1016","volume":"21","author":[{"given":"Daniel","family":"Zielonka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2014.12.013_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A\u00a0novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","author":"HDRG","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","article-title":"Huntington's disease","volume":"27","author":"Walker","year":"2007","journal-title":"Semin Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.parkreldis.2012.05.020","article-title":"Age at onset in Huntington's disease: replication study on the association of HAP1","volume":"18","author":"Karadima","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.parkreldis.2012.09.012","article-title":"The influence of gender on phenotype and disease progression in patients with Huntington's disease","volume":"19","author":"Zielonka","year":"2013","journal-title":"Park Relat Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ng0595-67","article-title":"Comparative sequence analysis of the human and pufferfish Huntington's disease genes","volume":"10","author":"Baxendale","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of Huntington's disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0896-6273(93)90127-D","article-title":"Huntington's disease gene (IT15) is widely expressed in human and rat tissues","volume":"11","author":"Li","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng1193-259","article-title":"Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues","volume":"5","author":"Strong","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib10","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/jcs.115.5.941","article-title":"Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease","volume":"115","author":"Hoffner","year":"2002","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","article-title":"Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis","volume":"67","author":"Godin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/exnr.1998.6832","article-title":"Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways","volume":"152","author":"Velier","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib14","doi-asserted-by":"crossref","first-page":"e108961","DOI":"10.1371\/journal.pone.0108961","article-title":"The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6\/2 mouse model","volume":"9","author":"Mielcarek","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib15","doi-asserted-by":"crossref","first-page":"e1004550","DOI":"10.1371\/journal.pgen.1004550","article-title":"Dysfunction of the CNS-heart axis in mouse models of Huntington's disease","volume":"10","author":"Mielcarek","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib16","first-page":"2547","article-title":"Cardiac dysfunction in Huntington's disease","volume":"20","author":"Zielonka","year":"2014","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington's Disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2202-9-38","article-title":"Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts","volume":"9","author":"Zhang","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0006-8993(98)01312-2","article-title":"Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene","volume":"818","author":"O'Kusky","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib23","first-page":"475","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neurosci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib25","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/pmic.201100380","article-title":"Mass spectrometric identification of novel posttranslational modification sites in Huntingtin","volume":"12","author":"Dong","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molcel.2004.09.016","article-title":"A\u00a0protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease","volume":"15","author":"Goehler","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coph.2007.12.002","article-title":"Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders","volume":"8","author":"Abel","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib29","doi-asserted-by":"crossref","first-page":"13201","DOI":"10.1073\/pnas.191498198","article-title":"Altered transcription in yeast expressing expanded polyglutamine","volume":"98","author":"Hughes","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI45364","article-title":"The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease","volume":"121","author":"Munoz-Sanjuan","year":"2011","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib32","doi-asserted-by":"crossref","first-page":"e1001717","DOI":"10.1371\/journal.pbio.1001717","article-title":"HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration","volume":"11","author":"Mielcarek","year":"2013","journal-title":"PLoS Biol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib33","doi-asserted-by":"crossref","first-page":"e80849","DOI":"10.1371\/journal.pone.0080849","article-title":"HDAC4 does not act as a protein deacetylase in the postnatal murine brain in\u00a0vivo","volume":"8","author":"Mielcarek","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib34","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib35","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in\u00a0vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib36","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.bbamcr.2008.07.007","article-title":"HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2","volume":"1783","author":"Scognamiglio","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington's disease: underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10897-007-9133-0","article-title":"Living at risk: concealing risk and preserving hope in Huntington disease","volume":"17","author":"Quaid","year":"2008","journal-title":"J\u00a0Genet Couns"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.parkreldis.2014.12.013_bib39","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1353-8020(11)70034-7","article-title":"Huntington's disease: new aspects on phenotype and genotype","volume":"18","author":"Shang","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib42","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A\u00a0majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol \u2013 CB"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib47","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4161\/rna.8.6.16035","article-title":"Micro RNA\u00a0\u2212214,\u2212150,\u2212146a and\u00a0\u2212125b target Huntingtin gene","volume":"8","author":"Sinha","year":"2011","journal-title":"RNA Biol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib50","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/gt.2011.170","article-title":"Using non-coding small RNAs to develop therapies for Huntington's disease","volume":"18","author":"Zhang","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib54","doi-asserted-by":"crossref","first-page":"e8025","DOI":"10.1371\/journal.pone.0008025","article-title":"Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease","volume":"4","author":"Moffitt","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib55","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.celrep.2012.11.001","article-title":"The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models","volume":"2","author":"Chopra","year":"2012","journal-title":"Cell Reports"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib56","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1172\/JCI57413","article-title":"Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease","volume":"121","author":"Labbadia","year":"2011","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/brain\/aws022","article-title":"Suppression of protein aggregation by chaperone modification of high molecular weight complexes","volume":"135","author":"Labbadia","year":"2012","journal-title":"Brain"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.parkreldis.2014.12.013_bib58","doi-asserted-by":"crossref","first-page":"16400","DOI":"10.1073\/pnas.182426599","article-title":"Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay","volume":"99","author":"Heiser","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib61","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib62","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib63","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib64","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0b013e3182885eb3","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"80","author":"Suchowersky","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib67","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A\u00a0randomized trial of amantadine in Huntington disease","volume":"60","author":"O'Suilleabhain","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib68","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","article-title":"IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study","volume":"60","author":"Lucetti","year":"2003","journal-title":"Neurology"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.parkreldis.2014.12.013_bib69","first-page":"S83","article-title":"Amantadine in Huntington's disease: open-label video-blinded study","volume":"23","author":"Lucetti","year":"2002","journal-title":"Neurol Sci \u2013 Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.63.3.597","article-title":"IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study","volume":"63","author":"Heckmann","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib71","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.parkreldis.2012.04.029","article-title":"Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients","volume":"18","author":"Fekete","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","article-title":"The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties","volume":"628","author":"Dyhring","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In\u00a0vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib74","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pnpbp.2005.03.003","article-title":"The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats","volume":"29","author":"Rung","year":"2005","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5","article-title":"Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity","volume":"28","author":"Tedroff","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib76","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1124\/jpet.106.102905","volume":"318","author":"Natesan","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib77","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/syn.20663","article-title":"The dopaminergic stabilizer ASP2314\/ACR16 selectively interacts with D2(High) receptors","volume":"63","author":"Seeman","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib78","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","article-title":"Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization","volume":"115","author":"Rung","year":"2008","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib79","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1476-5381.2010.01010.x","article-title":"Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor","volume":"161","author":"Kara","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib81","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in\u00a0patients with Huntington's disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib82","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","author":"Huntington Study Group HI","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib83","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/mds.25559","article-title":"The pridopidine paradox in Huntington's disease","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord \u2013 Off J Mov Disord Soc"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib84","doi-asserted-by":"crossref","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease","volume":"3","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib85","doi-asserted-by":"crossref","first-page":"RRN1261","DOI":"10.1371\/currents.RRN1261","article-title":"An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease","volume":"3","author":"Anderson","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib86","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington's disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib87","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/nmt.11.45","article-title":"Depression in the early stages of Huntington disease","volume":"1","author":"Epping","year":"2011","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib88","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and stages of Huntington's disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","article-title":"Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR","volume":"25","author":"Holl","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib90","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1176\/appi.ajp.162.4.725","article-title":"Critical periods of suicide risk in Huntington's disease","volume":"162","author":"Paulsen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib91","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0306-4522(95)00162-C","article-title":"Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease","volume":"68","author":"Peschanski","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib92","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nm0898-963","article-title":"Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease","volume":"4","author":"Palfi","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm0698-727","article-title":"Functional integration of striatal allografts in a primate model of Huntington's disease","volume":"4","author":"Kendall","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.expneurol.2006.11.007","article-title":"Stem cell transplantation for Huntington's disease","volume":"203","author":"Dunnett","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib95","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib96","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","article-title":"Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration","volume":"106","author":"Cicchetti","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib97","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.expneurol.2009.12.005","article-title":"Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation","volume":"222","author":"Gallina","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib98","first-page":"109","article-title":"The first homotopic fetal homograft of the striatum in the treatment of Huntington's disease","volume":"129","author":"Madrazo","year":"1993","journal-title":"Gac Medi Mex"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/exnr.1997.6685","article-title":"Safety of intrastriatal neurotransplantation for Huntington's disease patients","volume":"149","author":"Kopyov","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0361-9230(95)02029-2","article-title":"Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation","volume":"39","author":"Pundt","year":"1996","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib101","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1460-9568.1989.tb00375.x","article-title":"Intrinsic organization and connectivity of intrastriatal striatal transplants in rats as revealed by DARPP-32 immunohistochemistry: specificity of connections with the lesioned host brain","volume":"1","author":"Wictorin","year":"1989","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib102","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington's disease after neural transplantation","volume":"356","author":"Bachoud-Levi","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study","volume":"5","author":"Bachoud-Levi","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib104","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","article-title":"Bilateral human fetal striatal transplantation in Huntington's disease","volume":"58","author":"Hauser","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.20564","article-title":"Positron emission tomography after fetal transplantation in Huntington's disease","volume":"58","author":"Furtado","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib106","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/brain\/awq328","article-title":"Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications","volume":"134","author":"Cicchetti","year":"2011","journal-title":"Brain \u2013 J Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib107","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","article-title":"Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475","volume":"73","author":"Rosser","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","article-title":"The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease","volume":"84","author":"Barker","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib109","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/jnnp.2007.142380","article-title":"Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease","volume":"79","author":"Reuter","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib110","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib111","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/1531-8257(200011)15:6<1248::AID-MDS1029>3.0.CO;2-Q","article-title":"Internal globus pallidotomy in dystonia secondary to Huntington's disease","volume":"15","author":"Cubo","year":"2000","journal-title":"Mov Disord \u2013 Off J Mov Disord Soc"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib112","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1212\/01.WNL.0000094202.26313.73","article-title":"Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy","volume":"61","author":"Watarai","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib113","first-page":"295","article-title":"Pallidothalamotomy in chorea","volume":"64","author":"Spiegel","year":"1950","journal-title":"Arch Neurol Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib114","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","article-title":"Bilateral globus pallidus stimulation for Huntington's disease","volume":"56","author":"Moro","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib115","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/mds.23731","article-title":"Deep brain stimulation effects in dystonia: time course of electrophysiological changes in early treatment","volume":"26","author":"Ruge","year":"2011","journal-title":"Mov Disord \u2013 Off J Mov Disord Soc"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib116","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/mds.24959","article-title":"Deep brain stimulation in Huntington's disease: a 4-year follow-up case report","volume":"27","author":"Spielberger","year":"2012","journal-title":"Mov Disord \u2013 Off J Mov Disord Soc"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib117","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2013.11.007","article-title":"A\u00a05-year follow-up of deep brain stimulation in Huntington's disease","volume":"20","author":"Lopez-Sendon Moreno","year":"2014","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib118","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.parkreldis.2012.03.005","article-title":"Deep brain stimulation in disabling involuntary vocalization associated with Huntington's disease","volume":"18","author":"Garcia-Ruiz","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib119","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2648.2009.05217.x","article-title":"Huntington disease: families' experiences of healthcare services","volume":"66","author":"Skirton","year":"2010","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainresbull.2009.06.017","article-title":"Coordinated multidisciplinary care for Huntington's disease. An outpatient department","volume":"80","author":"Veenhuizen","year":"2009","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brainresbull.2006.10.027","article-title":"Comprehensive care in Huntington's disease: a physician's perspective","volume":"72","author":"Nance","year":"2007","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/nmt.11.86","article-title":"Physiotherapy clinical guidelines for Huntington's disease","volume":"2","author":"Quinn","year":"2012","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/nmt.11.69","article-title":"Nutritional management of individuals with Huntington's disease: nutritional guidelines","volume":"2","author":"Brotherton","year":"2012","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nmt.11.77","article-title":"Oral feeding in Huntington's disease: a guideline document for speech and language therapists","volume":"2","author":"Hamilton","year":"2012","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2217\/nmt.11.78","article-title":"Management of speech, language and communication difficulties in Huntington's disease","volume":"2","author":"Hamilton","year":"2012","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/nmt.11.68","article-title":"Guideline for oral healthcare of adults with Huntington's disease","volume":"2","author":"Manley","year":"2012","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.12.013_bib127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/nmt.11.81","article-title":"Development of guidelines for occupational therapy in Huntington's disease","volume":"2","author":"Cook","year":"2012","journal-title":"Neurodegen Dis Manage"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","article-title":"An evidence-based approach in the treatment of Huntington's disease","volume":"18","author":"Mestre","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.12.013_bib129","first-page":"717","article-title":"Hope in Huntington's disease. A survey in counselling patients with Huntington's disease, as well as the caregivers","volume":"4","author":"Marcinkowski","year":"2009","journal-title":"Neural Regen Res"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014004878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014004878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T18:16:22Z","timestamp":1650824182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802014004878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1353802014004878"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.013","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Huntington's disease: Advances in care and emerging therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}